HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998
Ned Sacktor,Robert H. Lyles,Richard L. Skolasky,C. Kleeberger,Ola A. Selnes,Eric N. Miller,James T. Becker,Bruce A. Cohen,Justin C. McArthur +8 more
TLDR
The proportion of new cases of HIV dementia with a CD4 count in a higher range since 1996 may be increasing, and the introduction of highly active antiretroviral therapy (HAART) may be responsible.Abstract:
This study examined the temporal trends in the incidence rates of HIV dementia, cryptococcal meningitis, toxoplasmosis, progressive multifocal leukoencephalopathy, and CNS lymphoma from January 1990 to December 1998 in the Multicenter AIDS Cohort Study. The incidence rates for HIV dementia, cryptococcal meningitis, and lymphoma decreased following the introduction of highly active antiretroviral therapy (HAART). The proportion of new cases of HIV dementia with a CD4 count in a higher range (i.e., 201 to 350) since 1996 may be increasing.read more
Citations
More filters
Journal ArticleDOI
Cognitive Neuropsychology of HIV-Associated Neurocognitive Disorders
TL;DR: An update on the nature, extent, and diagnosis of HAND is provided and the cognitive neuropsychology approach may enhance the ecological validity of neuroAIDS research and inform the development of much needed novel, targeted cognitive and behavioral therapies.
Journal ArticleDOI
Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort
Victor Valcour,C. Shikuma,Bruce Shiramizu,Michael R. Watters,P. Poff,Ola A. Selnes,P. S. Holck,John Grove,Ned Sacktor +8 more
TL;DR: Older age is associated with increased HAD in this HIV-1 cohort and underlying mechanisms are unclear but do not appear related to duration of HIV- 1 infection.
Journal ArticleDOI
HIV dementia: an evolving disease.
TL;DR: This overview will review some of the outstanding questions relating to HIV-dementia, including are there differing phenotypes or temporal patterns of progression in HIV-Dementia?
Journal ArticleDOI
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons.
Julie D. Rippeth,Robert K. Heaton,Catherine L. Carey,Thomas D. Marcotte,David J. Moore,Raul Gonzalez,Tanya Wolfson,Igor Grant +7 more
TL;DR: The results indicate that HIV infection and methamphetamine dependence are each associated with neuropsychological deficits, and suggest that these factors in combination are associated with additive deleterious cognitive effects.
Journal ArticleDOI
The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.
TL;DR: The incidence rates of HIV-associated neurological disease and central nervous system (CNS) opportunistic infections also are decreasing, and as patients develop increasing resistance mutations to antiretroviral drugs and with subsequent decline in CD4 cell counts, in the near future, the incidence of HIV’s neurological disease may begin to rise.
References
More filters
Journal Article
Surveillance for waterborne-disease outbreaks : united states, 1995-1996
TL;DR: In this paper, the authors reported a total of 22 waterborne-disease outbreaks associated with drinking water and recreational lake water, which caused an estimated total of 2,567 persons to become ill. No deaths were reported.
Journal ArticleDOI
The multicenter aids cohort study: rationale, organization, and selected characteristics of the participants
TL;DR: The Multicenter AIDS Cohort Study was designed to elucidate the natural history of the infection causing acquired immunodeficiency syndrome (AIDS), identify risk factors for occurrence and clinical expression of the virus, and establish a repository of biologic specimens for future study.
Journal ArticleDOI
Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection
Robert S. Janssen,David R. Cornblath,Leon G. Epstein,Richard P. Foa,Justin C. McArthur,Richard W. Price,Arthur K. Asbury,Alexandra Beckett,D. Frank Benson,T.Peter Bridge,Carl M. Leventhal,Paul Satz,Andrew J. Saykin,John J. Sidtis,Susan Tross,James T. Becker,Kenneth G. Castro,Bruce A. Cohen,Marshall F. Folstein,Francisco Gonzalez-Scarano,Igor Grant,Mario Maj,R. H. McAllister,M.-Marsel Mesulam,Eric N. Miller,Margaret J. Oxtoby,Norman Sartorius,Ola A. Selnes,Janet B. W. Williams,Michael Zaudig +29 more
TL;DR: These definitions have been developed in conjunction with the International Classification of Diseases-10 (ICD-10, unpublished draft of the World Health Organization) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, unpublishedDraft of the American Psychiatric Association) and are not identical.
Journal ArticleDOI
Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration
Roger Detels,Alvaro Muñoz,Glen McFarlane,Lawrence A. Kingsley,Joseph B. Margolick,Janis V. Giorgi,Lewis K. Schrager,John P. Phair +7 more
TL;DR: In the calendar period when potent antiretroviral therapy was introduced, the time to development of AIDS and time to death were extended, and rate of CD4 cell count decline was arrested.
Journal ArticleDOI
Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.
TL;DR: The incidence of AIDS-defining events in patients with advanced HIV infection at Frankfurt University Hospital has declined by more than 70% from 1992 to 1996, with a trend for malignancies and single opportunistic infections, with the exception of mycobacterial diseases.
Related Papers (5)
Updated research nosology for HIV-associated neurocognitive disorders
Andrea Antinori,Gabriele Arendt,James T. Becker,Bruce J. Brew,Desiree Byrd,Mariana Cherner,David B. Clifford,Paola Cinque,Leon G. Epstein,K. Goodkin,Magnus Gisslén,Igor Grant,Robert K. Heaton,Jeymohan Joseph,Karen Marder,Camillo Marra,Justin C. McArthur,Michael Nunn,Richard W. Price,Lynn Pulliam,Kevin Robertson,Ned Sacktor,Victor Valcour,Valerie Wojna +23 more
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Robert K. Heaton,David B. Clifford,Donald Franklin,Steven Paul Woods,Christopher Ake,Florin Vaida,Ronald J. Ellis,S. Letendre,Thomas D. Marcotte,Joseph H. Atkinson,Monica Rivera-Mindt,Ofilio Vigil,Michael J. Taylor,Ann C. Collier,Camillo Marra,Benjamin B. Gelman,Justin C. McArthur,Susan Morgello,David M. Simpson,McCutchan Ja,Ian Abramson,Anthony Gamst,Christine Fennema-Notestine,Terry L. Jernigan,Joseph K. Wong,Igor Grant +25 more